Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunotoxin therapy of hematologic malignancies.

Arthur E Frankel1, David M Neville, Thomas A Bugge

  • 1Wake Forest University School of Medicine, Winston-Salem, NC, USA.

Seminars in Oncology
|August 27, 2003
PubMed
Summary

Immunotoxins offer a promising new treatment for relapsed or refractory hematologic malignancies. These agents effectively target and eliminate chemoresistant cancer stem cells without causing myelosuppression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

DNA methylation-based classification of hematolymphoid neoplasms.

Blood advances·2026
Same author

Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant.

Blood·2026
Same author

Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cells.

Science translational medicine·2026
Same author

Expert consensus opinion on the management of hairy cell leukemia in elderly patients.

Leukemia & lymphoma·2025
Same author

Phase 2 trial of rituximab with either pentostatin or bendamustine for multiply relapsed or refractory hairy cell leukemia.

Blood·2025
Same author

Complete Response in Hairy Cell Leukemia to Anti-CD22 CAR T-Cell Therapy.

JCO precision oncology·2025

Area of Science:

  • Oncology
  • Immunology
  • Biochemistry

Background:

  • Hematologic malignancies often relapse or become refractory to chemotherapy, limiting treatment options.
  • Stem cell transplantation is effective but not suitable for all patients due to donor availability, age, or comorbidities.
  • There is a critical need for novel, non-myelosuppressive therapies targeting multidrug-resistant cancer stem cells.

Purpose of the Study:

  • To review the synthesis and therapeutic potential of immunotoxins for chemoresistant hematologic diseases.
  • To highlight the preclinical and clinical activity of novel immunotoxin agents.
  • To discuss the future clinical translation of immunotoxin therapies.

Main Methods:

  • Synthesis of immunotoxins by linking cell-selective ligands to peptide toxins.

Related Experiment Videos

  • Evaluation of immunotoxin activity through preclinical studies.
  • Assessment of clinical efficacy in patients with hematologic neoplasms.

    • Main Results:

    • Several synthesized immunotoxins demonstrated significant antitumor effects in preclinical models.
    • Clinical trials showed dramatic responses in patients with hematologic malignancies.
    • One immunotoxin has received US Food and Drug Administration (FDA) approval for therapeutic use.

    Conclusions:

    • Immunotoxins represent a viable therapeutic strategy for patients with refractory hematologic cancers.
    • The targeted delivery and cytotoxic mechanisms of immunotoxins overcome multidrug resistance.
    • Continued development and clinical application of immunotoxins are expected to expand treatment options.